Skip to main content
. 2014 Apr 24;110(10):2479–2488. doi: 10.1038/bjc.2014.220

Figure 5.

Figure 5

Single or combination AKT1/2 shRNAs and signalling intermediate inhibitor treatments in mesothelioma. (A) Imunoblotting evaluations of the effects of AKT inhibition on MDM2 activity and p53 and p21 expression in mesothelioma cell lines (MESO924 and MESO428) after treatment with GDC0941 for 72 h. β-Actin stain is a loading control. (B) Immunoblotting evaluations of AKT1/2 knockdown, inhibition of MDM2-p53-p21 axis in mesothelioma cell lines (MESO924 and MESO428) at 10 days after infection with AKT1/2 shRNA alone and in combination. β-Actin stain is a loading control. (C) Cell viability, in mesothelioma cell lines MESO924 and MESO428, was evaluated by the CellTiter-Glo luminescence assay after 3 and 6 days treatment with PI3K/mTOR (50 nM BEZ235), mTOR (20 nM RAD), MEK (10 μM U0126) inhibitors, or AKT1/2 shRNA (AKT1/2 shRNA stable expression), alone and together. The data were normalised to the DMSO and empty vector control, and represent the mean values (±s.d.) of quadruplicate cultures from two independent experiments. Statistically significant difference between untreated control and treatments is presented as *P<0.05, **P<0.01, ***P<0.001.